Loading company
Rigel Pharmaceuticals Inc.
RIGL · Nasdaq · ·
Next earnings: November 3, 2026
$48.88-0.9%Sep 29 close
- 1M
- +5.2%
- 6M
- +90.0%
- 1Y
- +72.5%
- 5Y
- +29.3%
RIGL · Nasdaq · ·
Next earnings: November 3, 2026
$48.88-0.9%Sep 29 close
Rigel Pharmaceuticals Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $78.7M | $101.7M | -22.60% |
| Profit | $17.3M | $59.6M | -71.00% |
| Profit per share | $0.88 | $3.28 | -73.17% |
| Free Cash Flow | -$22M | -$19.1M | -15.30% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Rigel delivered a strong second quarter, highlighted by record net product sales, continued profitability and the in-license of VEPPANU, the first and only FDA-approved PROTAC for patients with ER+/HER2-, ESR1 -mutated advanced or metastatic breast cancer. We expect VEPPANU to be commercially available later this month, further expanding our commercial business in hematology and oncology,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
In patients with immune thrombocytopenia (ITP), the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. Patients suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs), and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rigel Pharmaceuticals Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Rigel Pharmaceuticals Inc. has no earnings call transcript available.